Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 13, 2017 - Issue 9
Submit an article Journal homepage
1,637
Views
7
CrossRef citations to date
0
Altmetric
Research Papers

Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older

David P. GreenbergSanofi Pasteur, Swiftwater, PA, USA;Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USACorrespondence[email protected]
,
Corwin A. RobertsonSanofi Pasteur, Swiftwater, PA, USA
,
H. Keipp TalbotDepartment of Medicine, Vanderbilt University Medical Center, A2200 MCN, Nashville, TN, USA
&
Michael D. DeckerSanofi Pasteur, Swiftwater, PA, USA;Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN, USA
Pages 2058-2064 | Received 13 Mar 2017, Accepted 15 Jun 2017, Published online: 22 Sep 2017

References

  • Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012; 8:81-8; PMID: 22252006; https://doi.org/10.4161/hv.8.1.17623
  • Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28 Suppl 4:D45-53; PMID: 20713260; https://doi.org/10.1016/j.vaccine.2010.08.028
  • US Centers for Disease Conrol and Prevention. Prevention and control of influenza with vaccines: Interim recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013. MMWR Morb Mortal Wkly Rep 2013; 62:356 PMID: 23657110
  • Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993-8; PMID: 22226861; https://doi.org/10.1016/j.vaccine.2011.12.098
  • Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012; 30:7443-6; PMID: 23084849; https://doi.org/10.1016/j.vaccine.2012.10.025
  • US Food and Drug Administration. Fluzone Quadrivalent. [accessed http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm356091.htm
  • Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013; 31:770-6; PMID: 23228813; https://doi.org/10.1016/j.vaccine.2012.11.074
  • Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40; PMID: 15367555; https://doi.org/10.1001/jama.292.11.1333
  • Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86; PMID: 12517228; https://doi.org/10.1001/jama.289.2.179
  • Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Vaccine 2015; 33:2485-92; PMID: 25843270; https://doi.org/10.1016/j.vaccine.2015.03.065
  • Haq K, McElhaney JE. Immunosenescence: Influenza vaccination and the elderly. Curr Opin Immunol 2014; 29:38-42; PMID: 24769424; https://doi.org/10.1016/j.coi.2014.03.008
  • Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204:1879-85; PMID: 21998477; https://doi.org/10.1093/infdis/jir661
  • Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: Effect of end points used and characteristics of vaccine failures. J Infect Dis 2011; 203:1309-15; PMID: 21378375; https://doi.org/10.1093/infdis/jir015
  • Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: A focus on vaccines. Expert Rev Vaccines 2016; 15:967-76; PMID: 26954563; https://doi.org/10.1586/14760584.2016.1164046
  • Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines 2013; 12:519-36; PMID: 23659300; https://doi.org/10.1586/erv.13.35
  • Cox RJ. Correlates of protection to influenza virus, where do we go from here?. Hum Vaccin Immunother 2013; 9:405-8; PMID: 23291930; https://doi.org/10.4161/hv.22908
  • US Food and Drug Administration. Guidance for industry. Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Siliver Spring, MD: US FDA; 2015 Sep 15 [accessed 2017 Mar 2]. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm
  • Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP. Fluzone(R) High-Dose Influenza Vaccine. Expert Rev Vaccines 2016; 15:1495-505; PMID: 27813430; https://doi.org/10.1080/14760584.2016.1254044
  • Frey SE, Reyes MR, Reynales H, Bermal NN, Nicolay U, Narasimhan V, Forleo-Neto E, Arora AK. Comparison of the safety and immunogenicity of an MF59(R)-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014; 32:5027-34; PMID: 25045825; https://doi.org/10.1016/j.vaccine.2014.07.013
  • Pepin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 2013; 31:5572-8; PMID: 24016810; https://doi.org/10.1016/j.vaccine.2013.08.069

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.